BiotechTube
Home/Numab Innovation/Mireia Gómez-Angelats
MG

Mireia Gómez-Angelats

Chief Business Officer

Numab Innovation

Therapeutic Areas

ImmunologyOncologyOphthalmology

Numab Innovation Pipeline

DrugIndicationPhase
NM26Atopic DermatitisPre-clinical
NM81Inflammatory Bowel Disease (IBD)Pre-clinical
Boehringer Ingelheim Program 1Retinal DiseasesPre-clinical
Boehringer Ingelheim Program 2Oncology (T-cell engager)Pre-clinical

Leadership Team at Numab Innovation

BA
Barbara Angehrn
Chief Executive Officer
TG
Tea Gunde
VP Scientific Evaluation
View full Numab Innovation profile